Table 29Summary of probability and utility values for people without SCI

Parameter descriptionPoint estimateValue rangeProbability distributionDistribution parametersSource
Cohort probabilities
Treatment failure0.140.120–0.160Betaα = 139.165
β = 854.875
Lawrenson 2001255
First-line antibiotic resistant UTI0.080See textSee text
Multidrug resistant UTI0.0600.040–0.080Betaα = 27.9070
β = 437.2088
Expert opinion informed by al Hasan 2010, Cohennahu m 2008, Klevens 2008, Melzer 2007, Potz 2006, Reynolds 2009, Woodford 200410,79,227,294,379,398,514
Multidrug resistant mortality0.0260.013–0.051*Betaα = 7.8960
β = 297.1040
Klevens 2008227
Bacteraemia0.0360.034–0.038Betaα = 867.564
β = 23231.440
Saint 2000418
Bacteraemia mortality0.1270.091–0.176*Betaα = 28.0528
β = 192.9471
Bryan 198452
Utility per day of symptoms
No symptomatic UTI0.8580.775 – 0.943*Betaα = 55.6619
β = 9.1594
Jenkinson 1999207
Symptomatic UTI0.6740.608 – 0.741*Betaα = 129.5527
β = 62.5388
Ellis 2000120
First-line resistant UTI0.6300.568 – 0.692*Betaα = 147.1142
β = 86.1642
Ellis 2000, Ernst 2005120 123
Multi-drug resistant UTI0.6170.557 – 0.678*Betaα = 152.3615
β = 94.3569
Ellis 2000, Ernst 2005120 123
Bacteraemia0.5300.478 – 0.582*Betaα = 187.4700
β = 166.2470
Greenwell 2004, Selai 1995166,428
Urethral complications0.6170.557 – 0.678*Betaα = 152.3615
β = 94.3569
Expert opinion
Symptom duration (days)
Symptomatic UTI3.52.625–4.374*Gammaα = 61.5837
β = 0.0568
Expert opinion
First-line resistant UTI8.56.373–10.626*Gammaα = 61.3731
β = 0.1385
Expert opinion
Multidrug resistant UTI10.07.493–12.506*Gammaα = 61.1306
β = 0.1636
Expert opinion
Bacteraemia10.07.493–12.506*Gammaα = 61.1306
β = 0.1636
Expert opinion
Urethral complications10.07.493–12.506*Gammaα = 61.1306
β = 0.1636
Expert opinion
Equivalent mean utility per year (QALY)
No UTI0.858
Symptomatic UTI0.856
First-line resistant UTI0.853
Multidrug resistant UTI0.852
Bacteraemia0.850
Urethral complications0.852
*

Estimated based on mean and standard error – intended for the purpose of clinical validation only.

Adapted from reference

From: Appendix J, Cost-utility analysis: Intermittent self catheterisation

Cover of Infection: Prevention and Control of Healthcare-Associated Infections in Primary and Community Care
Infection: Prevention and Control of Healthcare-Associated Infections in Primary and Community Care: Partial Update of NICE Clinical Guideline 2.
NICE Clinical Guidelines, No. 139.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.